The global High Content Screening Market has been growing as a result of the rising demand for cell visualisation and quantification using cutting-edge technology. According to a study by Future Market Insights (FMI), the market is expected to reach a valuation of US$ 1.5 Bn by the end of 2021, driven by rising application in pharmaceutical and biotech companies. According to the study, the pharmaceutical and healthcare industries will account for more than 31% of the market’s demand in 2021.
For the discovery and development of new drugs, high content screening is used. Over the forecast years, rising research into novel drug candidates and target identification & validation is anticipated to drive uptake of high content screening. In addition, it is anticipated that continued efforts to produce high-quality, technologically advanced cell imaging systems will spur demand over the course of the forecast period.
However, the COVID 19 outbreak severely hampered the research and development efforts. The market is anticipated to suffer as a result of this. Nevertheless, it is anticipated that the market will grow in the upcoming years due to key manufacturers’ growing investments in the creation of advanced cell imaging products.
Key Takeaways of High Content Screening Market Study
- The high content screening market will rise at register a little below 5% y-o-y growth in 2021, following a brief period of restrictions amid COVID-19
- Presence of a sophisticated healthcare and pharmaceutical infrastructure is enabling the U.S. market account for over 90% of sales in North America
- The U.K. will register an impressive 7.2% y-o-y growth in 2021 driven by increasing focus on research and development activities in the pharmaceutical sector
- Demand registered in Germany and France is expected to rise significantly within Europe
- Favorable government policies will support expansion in Japan, followed by China
Who is Winning?
The leading suppliers in the high content screening market are working together and in partnerships to create new cell imaging technology. Leading manufacturers are collaborating with foreign labs and research institutions to create new imaging technologies as part of their business strategies.
For instance, Leica Microsystems and the European Molecular Biology Laboratory (EMBL) signed a collaboration agreement in December 2019 to develop new imaging technologies suitable for use in life science. Through this partnership, EMBL and Leica are advancing new imaging techniques for cell imaging.
High-Content-Screening Market by Category
Product Type
- Cell Imaging & Analysis
- HCS Instruments
- High-End HCS
- Mid End HCS
- Low-End HCS
- Flow Cytometers
- HCS Instruments
- Consumables
- Microplates
- Reagents & Assay Kits
- Other Consumables
- Softwares
- Services
Industry
- Pharmaceutical & Healthcare
- Biotechnology
- Educational Institutions
- Independent CRO
- Government Organizations
- Others
Application
- Primary & Secondary Screening
- Target Identification & Validation
- Toxicity Studies
- Compound Profiling
- Others
Region
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- The Middle East and Africa (MEA)
Valuable Insights into High Content Screening Market Study
Future Market Insights offers actionable insights and a unique perspective on the high content screening market in its latest study, presenting a historical demand assessment from 2016 – 2020 and projections from 2021–2031 based on the product (cell imaging & analysis, consumables, Software, services), industry (pharmaceutical & healthcare, biotechnology, educational institutions, independent CRO, government organizations and others), and by application (primary & secondary screening, target identification & validation, toxicity studies, compound profiling and others) in seven key regions.
